BRPI0606768A2 - forma de dosagem oral compreendendo rosiglitazona - Google Patents
forma de dosagem oral compreendendo rosiglitazonaInfo
- Publication number
- BRPI0606768A2 BRPI0606768A2 BRPI0606768-9A BRPI0606768A BRPI0606768A2 BR PI0606768 A2 BRPI0606768 A2 BR PI0606768A2 BR PI0606768 A BRPI0606768 A BR PI0606768A BR PI0606768 A2 BRPI0606768 A2 BR PI0606768A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- composition
- oral dosage
- rosiglitazone
- pellets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FORMA DE DOSAGEM ORAL COMPREENDENDO ROSIGLITAZONA. Uma forma de dosagem oral compreendendo pelotas de uma primeira composição e pelotas de uma segunda composição, cada composição compreendendo 5-[4-[2-(N-metil-N-(2 piri-dil)amino)etóxi]benzil]tiazolidina-2,4-diona ou um sal ou solvato farmaceuticamente aceitável deste e um veículo farmaceuticamente aceitável para este, em que a primeira e a segunda composição são organizadas para liberar droga em taxas de liberação diferentes na administração, de preferência tal que a taxa de liberação da droga a partir da forma de dosagem seja consideravelmente independente de pH; um processo para preparar tal forma de dosagem e o uso de tal forma de dosagem na medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0502479.9A GB0502479D0 (en) | 2005-02-07 | 2005-02-07 | Novel compositions |
PCT/EP2006/000999 WO2006082089A1 (en) | 2005-02-07 | 2006-02-03 | Oral dosage form comprising rosiglitazone |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0606768A2 true BRPI0606768A2 (pt) | 2009-07-14 |
Family
ID=34355902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606768-9A BRPI0606768A2 (pt) | 2005-02-07 | 2006-02-03 | forma de dosagem oral compreendendo rosiglitazona |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080139624A1 (pt) |
EP (1) | EP1845977A1 (pt) |
JP (1) | JP2008529984A (pt) |
KR (1) | KR20070104392A (pt) |
CN (1) | CN101155585A (pt) |
AU (1) | AU2006210135A1 (pt) |
BR (1) | BRPI0606768A2 (pt) |
CA (1) | CA2595409A1 (pt) |
EA (1) | EA200701680A1 (pt) |
GB (1) | GB0502479D0 (pt) |
IL (1) | IL184787A0 (pt) |
MA (1) | MA29280B1 (pt) |
MX (1) | MX2007009493A (pt) |
NO (1) | NO20074514L (pt) |
TW (1) | TW200640455A (pt) |
WO (1) | WO2006082089A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
CA2673418A1 (en) * | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical compound and composition |
KR20100129761A (ko) | 2008-03-11 | 2010-12-09 | 다케다 야쿠힌 고교 가부시키가이샤 | 경구 붕해 고형 제제 |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
US20100068283A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex VIVO modifiable particle or polymeric material medicament carrier |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
CN109481419B (zh) * | 2019-01-16 | 2021-04-02 | 中国人民解放军陆军军医大学第一附属医院 | 一种罗格列酮纳米制剂及其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US8802139B2 (en) * | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
AR045330A1 (es) * | 2003-08-07 | 2005-10-26 | Sb Pharmco Inc | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla |
EP1732513A2 (en) * | 2003-12-31 | 2006-12-20 | Alpharma, Inc. | Rosiglitazone formulations |
-
2005
- 2005-02-07 GB GBGB0502479.9A patent/GB0502479D0/en not_active Ceased
-
2006
- 2006-02-03 KR KR1020077018030A patent/KR20070104392A/ko not_active Application Discontinuation
- 2006-02-03 AU AU2006210135A patent/AU2006210135A1/en not_active Abandoned
- 2006-02-03 EA EA200701680A patent/EA200701680A1/ru unknown
- 2006-02-03 WO PCT/EP2006/000999 patent/WO2006082089A1/en active Application Filing
- 2006-02-03 MX MX2007009493A patent/MX2007009493A/es not_active Application Discontinuation
- 2006-02-03 US US11/815,333 patent/US20080139624A1/en not_active Abandoned
- 2006-02-03 JP JP2007553551A patent/JP2008529984A/ja not_active Withdrawn
- 2006-02-03 BR BRPI0606768-9A patent/BRPI0606768A2/pt not_active IP Right Cessation
- 2006-02-03 CN CNA2006800111169A patent/CN101155585A/zh active Pending
- 2006-02-03 CA CA002595409A patent/CA2595409A1/en not_active Abandoned
- 2006-02-03 EP EP06701697A patent/EP1845977A1/en not_active Withdrawn
- 2006-02-06 TW TW095103943A patent/TW200640455A/zh unknown
-
2007
- 2007-07-23 IL IL184787A patent/IL184787A0/en unknown
- 2007-08-31 MA MA30181A patent/MA29280B1/fr unknown
- 2007-09-05 NO NO20074514A patent/NO20074514L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1845977A1 (en) | 2007-10-24 |
US20080139624A1 (en) | 2008-06-12 |
CA2595409A1 (en) | 2006-08-10 |
IL184787A0 (en) | 2007-12-03 |
NO20074514L (no) | 2007-09-05 |
GB0502479D0 (en) | 2005-03-16 |
EA200701680A1 (ru) | 2007-12-28 |
MX2007009493A (es) | 2007-09-19 |
MA29280B1 (fr) | 2008-02-01 |
WO2006082089A1 (en) | 2006-08-10 |
CN101155585A (zh) | 2008-04-02 |
JP2008529984A (ja) | 2008-08-07 |
KR20070104392A (ko) | 2007-10-25 |
TW200640455A (en) | 2006-12-01 |
AU2006210135A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
BRPI0607803A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
BR0108870A (pt) | Sais cloridrato de 5-[4-[2-(n-metil-n-(2-piridil) amino) etoxi] benzil] tiazolidino-2,4-diona | |
PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
AR045330A1 (es) | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
DK1446404T3 (da) | Rosiglitazonedisylater og deres anvendelse som antidiabetika | |
BRPI0607804A2 (pt) | braçadeira de lámina despeladora com ranhuras de saìda de gordura | |
BR0112981A (pt) | Sais tartarato de derivado de tiazolidinadiona | |
BR0112982A (pt) | Sal tartarato de derivado de tiazolidinadiona | |
BR0112984A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
CY1107421T1 (el) | Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης | |
BR0111536A (pt) | Sal de tiazolidinediona para tratamento de diabetes mellitus | |
CY1107767T1 (el) | Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο | |
AP1738A (en) | Sodium salts of 5-[4-[2-(N-Methyl -N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
EP1867343A3 (en) | Inclusion complexes of a cyclodextrin with a thiazolidine-2,4-dione | |
CY1106397T1 (el) | Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο | |
ECSP003434A (es) | Nuevos compuestos | |
TH85149B (th) | รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน | |
TH84984B (th) | รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน | |
TH85149A (th) | รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SMITHKLINE BEECHAM (CORK) LIMITED (IE) Free format text: TRANSFERIDO DE: SB PHARMCO PUERTO RICO INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |